Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations-Reference-Cited by-同舟云学术

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations

Published:2016-05-25 Issue:3 Volume:157 Page:511-516
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Lewin R.,Sulkes A.,Shochat T.,Tsoref D.,Rizel S.,Liebermann N.,Hendler D.,Neiman V.,Ben-Aharon I.,Friedman E.,Paluch-Shimon S.,Margel D.,Kedar I.,Yerushalmi R.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-016-3836-6.pdf

Reference30 articles.

1. Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 343:692–695

2. Easton D, Thompson D, McGuffog L et al (1999) Cancer risks in BRCA2 mutation carriers. Breast cancer linkage consortium. J Natl Cancer Inst 91:1310–1316

3. Thompson D, Easton DF (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365

4. Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130

5. Begg CB, Haile RW, Borg A et al (2008) Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299:194–201

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization;Breast Cancer Research and Treatment;2024-04-03

2. The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy;Breast Cancer Research and Treatment;2024-02-12

3. The Impact of Germline BRCA Mutations in Locally Advanced, Triple Negative Breast Cancer Treated with Platinum Based Neoadjuvant Chemotherapy;2023-12-26

4. Progress and prospects in research and clinical practice of hormone receptor-positive, HER-2-negative breast cancer with BRCA1/2 mutations;Discover Oncology;2023-06-23

5. Systemic treatment of breast cancer in young patients with a germline mutation in the BRCA1 and BRCA2 genes;Onkologie;2023-06-16